AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 141 min read$ANIP

Cook Meredith sold $41K of ANIP

Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) sold 500 shares of ANI PHARMACEUTICALS INC (ANIP) at $81.84 on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cook Meredith
Published Jul 14, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIP
Neutral
high confidence
Mentioned
$ANIP
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale of 500 shares at $81.84 on 2026-07-13, with holdings after the trade of 77,390 shares.

02

Market read

Traders may briefly monitor insider activity, but a 10b5-1 sale of ~$40.9K is generally not a fundamental catalyst.

03

What to watch

The transaction size is small relative to typical institutional flows, and 10b5-1 plans are designed to reduce timing-based inference.

Relevance 2/10Novelty 3/10Timing: Filed on 2026-07-14 for a sale executed on 2026-07-13.

Background

This is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals, reported by an officer (SR. VP, General Counsel & SEC).

Company-level read

Ticker impact

$ANIPNeutralHigh confidence
Context

Meredith Cook, ANI Pharmaceuticals’ General Counsel, sold 500 shares on 2026-07-13 at $81.84 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact would be limited to intraday sentiment around the filing.

Evidence & confidence

The filing is a Form 4 open-market sale, explicitly under a pre-arranged 10b5-1 plan, and the disclosed transaction value is about $40.9K.

Market effects

Sector

No clear read-across to the biotech/pharma sector from a single planned insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even planned 10b5-1 sales can coincide with internal views on liquidity or risk, so some traders may still treat it as a mild negative sentiment signal.

Key entities

  • issuer
    ANI Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Meredith Cook

    Officer (SR. VP, General Counsel & SEC) who executed the sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIP insider trading history →

Related articles

OCT 12
$ANIPHighAI 8/10

ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study

ANI Pharmaceuticals (ANIP) reported positive results from its Phase 4 SYNCHRONICITY trial for the Fluocinolone Acetonide Intravitreal Implant in treating chronic non-infectious uveitis affecting the posterior segment of the eye. The trial met primary endpoints at six months and maintained improvements through 24 months. The implant is approved in the U.S. for chronic NIU-PS and diabetic macular edema. ANIP's stock closed at $73.89, up 2.65%.

rttnews.com2 min
OCT 12
$ANIPMedAI 8/10

ANI reports positive results from uveitis implant trial

ANI Pharmaceuticals (NASDAQ:ANIP) reported positive Phase 4 trial results for its fluocinolone acetonide implant in treating chronic non-infectious uveitis. The trial met primary endpoints, showing sustained improvements in visual acuity and central subfield thickness over 24 months. Adverse events included ocular hypertension and cataract. The implant was previously FDA-approved for diabetic macular edema and uveitis treatment.

investing.com2 min
OCT 12
$ANIPMedAI 8/10

After one implant, 79.6% of treated eyes had no inflammation return for two years

ANI Pharmaceuticals reported 6-month and 24-month data from its SYNCHRONICITY trial of fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis. The trial met co-primary endpoints with statistical significance, showing improvements in visual acuity and central subfield thickness. At 24 months, 79.6% of treated eyes had no inflammation recurrence. Adverse events were consistent with prior trials.

stocktitan.net2 min
SEP 30
$ANIPMedAI 8/10

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals (ANIP) will present data from its Phase 4 SYNCHRONICITY trial and post-hoc analyses from the NEW DAY trial at the American Academy of Ophthalmology 2026 Meeting. The trials involve Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis and diabetic macular edema. The company also plans an encore presentation at the Hawaiian Eye & Retina 2027 Meeting.

globenewswire.com1 min